English Journal

Pharmacological antioxidant strategies as therapeutic interventions for COPD.

Rahman I.AbstractCigarette/tobacco smoke/biomass fuel-induced oxidative and aldehyde/carbonyl stress are intimately associated with the progression and exacerbation of chronic obstructive pulmonary disease (COPD). Therefore, targeting systemic and local oxidative stress with antioxidants/redox modulating agents, or boosting the endogenous levels of antioxidants are likely to have beneficial effects in the treatment/management of COPD. Various antioxidant agents, such as thiol molecules (glutathione and mucolytic drugs, such as N-acetyl-L-cysteine and N-acystelyn, erdosteine, fudosteine, ergothioneine, and carbocysteine), have been reported to modulate various cellular and biochemical aspects of COPD. These antioxidants have been found to scavenge and detoxify free radicals and oxidants, regulate of glutathione biosynthesis, control nuclear factor-kappaB (NF-kappaB) activation, and hence inhibiting inflammatory gene expression. Synthetic molecules, such as specific spin traps like α-phenyl-N-tert-butyl nitrone, a catalytic antioxidant (ECSOD mimetic), porphyrins (AEOL 10150 and AEOL 10113), and a superoxide dismutase mimetic M40419, iNOS and myeloperoxidase inhibitors, lipid peroxidation inhibitors/blockers edaravone, and lazaroids/tirilazad have also been shown to have beneficial effects by inhibiting cigarette smoke-induced inflammatory responses and other carbonyl/oxidative stress-induced cellular alterations. A variety of oxidants, free radicals, and carbonyls/aldehydes are implicated in the pathogenesis of COPD, it is therefore, possible that therapeutic administration or supplementation of multiple antioxidants and/or boosting the endogenous levels of antioxidants will be beneficial in the treatment of COPD. This review discusses various novel pharmacological approaches adopted to enhance lung antioxidant levels, and various emerging beneficial and/or prophylactic effects of antioxidant therapeutics in halting or intervening the progression of COPD. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.
Biochimica et biophysica acta.Biochim Biophys Acta.2011 Nov 9. [Epub ahead of print]
Cigarette/tobacco smoke/biomass fuel-induced oxidative and aldehyde/carbonyl stress are intimately associated with the progression and exacerbation of chronic obstructive pulmonary disease (COPD). Therefore, targeting systemic and local oxidative stress with antioxidants/redox modulating agents, or
PMID 22101076

Sensitive LC-MS-MS method for the determination of tiopronin in human plasma.

Jiang B, Xu Y, Xu F, Sun J, Li N, Luo Y, Guo Q.SourceDepartment of Chemistry, University of Science and Technology of China, Hefei 230026, China.
Biomedical chromatography : BMC.Biomed Chromatogr.2010 Jun;24(6):655-62.
A highly selective and sensitive LC-MS-MS method was developed and validated to quantify tiopronin in human plasma, using fudosteine as the internal standard (IS). L-Cysteine and 1,4-dithiothreitol (DTT) were used as the reducer and the stabilizer to release and stabilify tiopronin from a dimmer and
PMID 19816855

Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine.

Osoata GO, Hanazawa T, Brindicci C, Ito M, Barnes PJ, Kharitonov S, Ito K.SourceAirway Disease Section, National Heart and Lung Institute, Imperial College London, London, UK.
Chest.Chest.2009 Jun;135(6):1513-20. Epub 2009 Feb 2.
BACKGROUND: Peroxynitrite (PN) formed by the reaction of nitric oxide and superoxide is a powerful oxidant/nitrosant. Nitrative stress is implicated in COPD pathogenesis, but PN has not been detected due to a short half-life (< 1 s) at physiologic condition. Instead, 3-nitrotyrosine has been meas
PMID 19188555

Japanese Journal

High-throughput determination of fudosteine in human plasma by liquid chromatography-tandem mass spectrometry, following protein precipitation in the 96-well plate format

WEN Jun,WU Yiwen,ZHANG Linli,QI Yunpeng,FAN Guorong,WU Yutian,LI Zhen
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 867(1), 153-159, 2008-05-01
NAID 10028000744

Experimental therapeutic efficacy of fudosteine, a novel expectorant of cysteine derivative : Its reductive effects on the goblet cell increase induced by lipopolysaccharide or isoproterenol, and on the ratio of fucose/sialic acid in sputa